MULTIPLE MYELOMA

In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma.

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MBBS, discussed with participants the tolerability and optimal use of therapies for newly-diagnosed multiple myeloma.

During a Targeted Oncology case-based roundtable event, Natalie S. Callander, MD, discussed studies that support alternative combination regimens after early relapse on bortezomib, lenalidomide, and dexamethasone for multiple myeloma.

Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, discussed the impact of new advancements in the treatment of multiple myeloma, like the use of BiTE cells, on the current and future landscape for this patient population.

Joshua Richter, MD, provides insight on the impact of the addition of daratumumab to treatments for patients with multiple myeloma.

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.

Dr Shaji Kumar outlines advice for community oncologists and discusses unmet needs for treating patients with R/R multiple myeloma.

Dr Kumar shares his perspective on the impact of management and monitoring strategies used to minimize the risk of adverse events in patients treated with teclistamab and other bispecifics.

Dr Shaji Kumar highlights bispecifics under development and how BCMA-targeting therapies impact patient selection for the treatment of R/R multiple myeloma.

Dr Shaji Kumar reviews key efficacy and safety outcomes of the updated data from MajesTEC-1, evaluating teclistamab in patients with R/R multiple myeloma.

Shaji Kumar, MD, presents a case of a 63-year-old woman with R/R multiple myeloma, shares his initial impression, and assess how clinical relapse impacts treatment decisions in patients with R/R multiple myeloma.

One of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.

A 54-year-old woman received a diagnosis of Revised International Staging System stage II multiple myeloma. Marc J. Braunstein, MD, PhD discussed the case with a group of peers.

BCMA/CD19 dual-targeting FasTCAR-T cells showed a high objective response rate in a study of patients with newly diagnosed high-risk multiple myeloma.

Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.

Results from MonumenTAL-1 presented during the 2022 ASH annual Meeting have led to the submission of a biologics license application for talquetamab.

In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.

Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.

Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.

Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.

In the CC-92480-MM-001, mezigdomide With dexamethasone demonstrated positive safety and efficacy in patients with heavily-pretreated multiple myeloma.

Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.

Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.

The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.